Telix Pharmaceuticals (NASDAQ:TLX) Stock Jumps 0.5% - Should You Buy?

Key Points

• Telix Pharmaceuticals shares rose 0.5% to $10.74 in midday trading, while volume was 43% below the average daily level.
• Analyst sentiment is broadly positive: four analysts rate the stock a Buy and one rates it Hold, producing a consensus “Moderate Buy” rating and a $20.50 price target.
• Telix develops radiopharmaceuticals and targeted radiation treatments, with Illuccix—an imaging agent for detecting prostate cancer lesions—as its primary commercial product.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price was up 0.5% on Monday. The company traded as high as $10.85 and last traded at $10.74. Approximately 249,389 shares were traded during mid-day trading, a decline of 43% from the average daily volume of 434,302 shares. The stock had previously closed at $10.69.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wedbush restated an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday, September 23rd. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, August 21st. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Friday, September 25th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday, September 21st. Finally, Citigroup reiterated a "buy" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.50.

Telix Pharmaceuticals Price Performance

The firm has a fifty day simple moving average of $11.50 and a two-hundred day simple moving average of $10.77. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently made changes to their positions in TLX. Hennion & Walsh Asset Management Inc. bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth $1,731,000. Private Advisor Group LLC increased its holdings in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock worth $1,669,000 after acquiring an additional 128,070 shares during the last quarter. XY Capital Ltd increased its holdings in Telix Pharmaceuticals by 468.0% in the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company's stock worth $822,000 after acquiring an additional 58,739 shares during the last quarter. WoodTrust Financial Corp bought a new stake in Telix Pharmaceuticals in the 3rd quarter valued at about $186,000. Finally, Bank of America Corp DE raised its stake in Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock valued at $96,000 after acquiring an additional 8,423 shares during the period.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its technologies are designed to help identify disease through medical imaging and, in some cases, deliver radiation directly to targeted cancer cells.

The company's primary commercial product is Illuccix (kit for the preparation of gallium-68 gozetotide injection), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in adults with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.